From a gout mainstay to novel autoimmune therapies: The hunt for a long COVID panacea
Scientists are looking at repurposing existing treatments as well as new agents targeting fatigue and inflammation
After producing vaccines and treatments for acute COVID-19 in record time, researchers are turning to finding a cure for long COVID, a more elusive target marked by hundreds of different symptoms afflicting millions of people.
Leading drug makers, including those that launched antiviral pills and monoclonal antibodies for the disease, are having early discussions with researchers about how to target post-acute COVID-19 syndrome, US and UK scientists told Reuters.
